Want to see GB:DXRX full AI Analyst Report?
Top Page
Diaceutics
(LSE:DXRX)
Select Model
Select Model
Rating:62Neutral
Price Target:
197.00 p
▲(37.28% Upside)
Action:Reiterated
Date:09/23/26
The score is primarily supported by a conservatively financed balance sheet and improving fundamentals (return to net profit and positive free cash flow in 2025). Offsetting this are a highly stretched valuation (very high P/E) and technicals that look overheated (very high RSI/Stoch), which raise the risk of a pullback despite an overall upward trend.
Positive Factors
Conservative balance sheet
Very low leverage and a sizable equity base provide financial flexibility for ongoing operations and investment. Stable, modest debt reduces balance-sheet pressure and leaves the company better positioned to fund growth or absorb business volatility over the next several quarters.
Negative Factors
Operating profitability remains unproven
The return to a small net profit has not yet translated into consistent operating profitability. A slightly negative operating result and a very thin net margin leave limited room for execution setbacks, making durable earnings conversion an important unresolved business issue.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a sizable equity base provide financial flexibility for ongoing operations and investment. Stable, modest debt reduces balance-sheet pressure and leaves the company better positioned to fund growth or absorb business volatility over the next several quarters.
Read all positive factors
Diaceutics (DXRX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£172.63M
Dividend YieldN/A
Average Volume (3M)368.77K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth20.14%
EPS Growth82.22%
CountryUK
Employees205
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding85,234,250
10 Day Avg. Volume256,461
30 Day Avg. Volume368,773
Financial Highlights & Ratios
PEG Ratio-11.04
Price to Book (P/B)2.67
Price to Sales (P/S)2.82
P/FCF Ratio75.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£215.00Price Target Upside49.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)£46.73M
Diaceutics Business Overview & Revenue Model
Company Description
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and imple...
How the Company Makes Money
Diaceutics primarily makes money by selling diagnostics-related intelligence and services to pharmaceutical and biotechnology companies that market or develop precision-medicine therapies requiring biomarker testing. Key revenue streams typically ...
Diaceutics Earnings Call Summary
Earnings Call Date:Sep 17, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Mar 15, 2027
Earnings Call Sentiment Positive
The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.Positive Updates
Revenue Growth
Revenue increased to GBP 12.3 million, up 24% or 28% on a constant currency basis, with 55% of revenue now being subscription-based.
Negative Updates
EBITDA Loss
EBITDA loss widened to negative GBP 1.3 million compared to negative GBP 200,000 in June 2023.
Read all updates
Q2-2024 Updates
Positive
Negative
Revenue Growth
Revenue increased to GBP 12.3 million, up 24% or 28% on a constant currency basis, with 55% of revenue now being subscription-based.
Read all positive updates
Company Guidance
In the Q2 2024 earnings call for Diaceutics, CEO Ryan Keeling detailed significant advancements achieved in the first half of the year, particularly emphasizing the launch of their PMx solution. The company has expanded its lab network, notably integrating rare disease data and enhancing European data capabilities, all contributing to a robust and automated data pipeline. This automation, aided by AI, has streamlined data handling from extraction to customer delivery. The PMx solution, which emerged as a pivotal development, has transformed their approach by directly engaging physicians with patient data, boosting engagement and conversion rates. The financial health of the company is strong, with a 24% revenue increase to £12.3 million and a gross profit margin of 87%. Diaceutics aims to transition to a 70% subscription-led revenue model by 2025, with recurring revenues currently at 55%. The company also reported a record order book of £27.9 million, with plans to achieve profitability and free cash flow generation by 2025.Diaceutics Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.33M | 38.44M | 32.16M | 23.70M | 19.50M | 13.94M |
| Gross Profit | 28.02M | 26.12M | 28.27M | 19.71M | 14.04M | 10.57M |
| EBITDA | 5.53M | 6.08M | 2.77M | 2.36M | 3.61M | 2.35M |
| Net Income | -271.00K | 97.00K | -1.70M | -1.75M | 724.00K | 561.00K |
Balance Sheet | ||||||
| Total Assets | 52.15M | 50.01M | 48.62M | 46.34M | 48.26M | 45.01M |
| Cash, Cash Equivalents and Short-Term Investments | 8.10M | 7.34M | 12.74M | 16.67M | 19.84M | 19.68M |
| Total Debt | 2.09M | 1.15M | 1.06M | 1.21M | 1.33M | 1.56M |
| Total Liabilities | 13.40M | 9.53M | 8.76M | 5.56M | 5.74M | 4.36M |
| Stockholders Equity | 38.75M | 40.48M | 39.86M | 40.79M | 42.51M | 40.65M |
Cash Flow | ||||||
| Free Cash Flow | 4.08M | 1.43M | -3.98M | -3.54M | 278.00K | -5.03M |
| Operating Cash Flow | 4.12M | 1.50M | 651.00K | 1.31M | 5.15M | 570.00K |
| Investing Cash Flow | -6.07M | -6.45M | -4.03M | -4.21M | -4.87M | -5.60M |
| Financing Cash Flow | -371.00K | -333.00K | -64.00K | -239.00K | -132.00K | -270.00K |
Diaceutics Technical Analysis
Positive
143.50
Price Trends
177.42
Positive
159.65
Positive
159.20
Positive
Market Momentum
6.08
Positive
67.85
Neutral
55.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:DXRX, the sentiment is Positive. The current price of 143.5 is below the 20-day moving average (MA) of 200.85, below the 50-day MA of 177.42, and below the 200-day MA of 159.20, indicating a bullish trend. The MACD of 6.08 indicates Positive momentum. The RSI at 67.85 is Neutral, neither overbought nor oversold. The STOCH value of 55.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:DXRX.
Diaceutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | £102.71M | 41.38 | 3.58% | 4.36% | 2.26% | -57.04% | |
62 Neutral | £172.63M | -635.94 | -0.68% | ― | 20.14% | 82.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% | |
48 Neutral | £6.82M | -0.49 | -104.73% | ― | -56.10% | 41.10% | |
40 Underperform | £14.45M | -0.27 | -451.74% | ― | 33.37% | 86.41% | |
40 Underperform | £36.54M | -3.44 | 675.00% | ― | ― | ― |
* Healthcare Sector Average
GB:DXRX
Diaceutics
203.50
35.50
21.13%
GB:CLBX
ANGLE plc
0.60
-1.80
-75.00%
GB:EKF
EKF Diagnostics Holdings
24.00
-2.35
-8.92%
GB:GDR
Genedrive
0.98
-0.06
-5.43%
GB:OBD
Oxford BioDynamics
0.11
-0.21
-66.56%
GB:RENX
Renalytix
5.45
-2.80
-33.94%
Diaceutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Diaceutics boosts recurring revenue and widens market with ‘Precision For All’ strategy
Positive
Sep 22, 2026
Diaceutics reported strong interim results for the six months to 30 June 2026, with annual recurring revenue jumping 79% to £29.4 million and total revenue up 22% on a constant currency basis to £17.5 million. The company lifted gross ma...
Business Operations and StrategyFinancial Disclosures
Diaceutics to Unveil Half-Year 2026 Results and Step Up Investor Outreach
Positive
Sep 8, 2026
Diaceutics PLC, the diagnostics intelligence and engagement specialist focused on improving access to precision therapies, plans to release its unaudited half-year results for the six months to 30 June 2026 on 22 September 2026. The company, whose...
Business Operations and StrategyRegulatory Filings and Compliance
Diaceutics issues new shares under incentive plans, updates total voting rights
Neutral
Sep 2, 2026
Diaceutics PLC has reported ongoing share purchases by three senior executives under its UK and Global Share Incentive Plans, with trustees acquiring ordinary shares on behalf of the PDMRs and the company matching these with conditional share awar...
Business Operations and Strategy
Diaceutics and PCC Launch NGS Study to Boost Confidence in Cancer Diagnostics
Positive
Aug 20, 2026
Diaceutics PLC and the Precision Cancer Consortium have launched an NGS Concordance Study to evaluate how consistently genomic variants are detected across next-generation sequencing panels and platforms used in routine U.S. clinical practice. The...
Business Operations and StrategyRegulatory Filings and Compliance
Diaceutics boosts employee share incentives and updates total voting rights
Positive
Aug 4, 2026
Diaceutics PLC has expanded its employee share ownership framework, with trustees of its 2020 Employee Benefit Trust purchasing ordinary shares on behalf of three senior executives under the UK and Global Share Incentive Plan. The company is match...
Business Operations and StrategyFinancial Disclosures
Diaceutics boosts recurring revenue and order book, sharpening 2026 outlook
Positive
Jul 29, 2026
Diaceutics reported strong first-half 2026 performance, with revenue up 22% on a constant currency basis to £17.5 million and Annual Recurring Revenue surging 75% to £28.8 million. The company’s recurring revenue now accounts for a...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Diaceutics updates on executive share incentive purchases and expanded share capital
Positive
Jul 3, 2026
Diaceutics has reported that trustees of its 2020 Employee Benefit Trust have been purchasing ordinary shares on behalf of senior executives under its UK and Global Share Incentive Plans, with the company matching employee purchases on a 1:1 basis...
Stock BuybackShareholder Meetings
Diaceutics Wins Shareholder Backing for All AGM Resolutions
Positive
Jun 25, 2026
Diaceutics PLC reported that shareholders approved all resolutions at its latest Annual General Meeting, underscoring strong investor backing for the company’s governance and strategic direction. The meeting saw solid support for the company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.